reSee.it Video Transcript AI Summary
There was a recent FDA rejection of an MDMA-based therapy for PTSD, a program that had achieved, on its own terms, two successful phase three studies. The speaker notes that the trials were designed exactly as the FDA told them to design, but the episode is tied to the rise of advisory committees—FDA panels of so-called experts who opine on data and recommendations. The FDA is not bound by their recommendations, but they often follow them, sometimes not. In the speaker’s view, the FDA uses these advisory committees as a cover for what they actually want to do, a dynamic the speaker has observed across years in biotech as an investor and company builder. He has sat in eight-hour advisory committee sessions in Maryland, taking detailed notes, and while he didn’t attend the most recent one, he believes it smelled like the briefing documents provided to the committee were used to guide the outcome. He suspects the advisory committee recommended against approval, and the FDA then moved to that outcome.
The speaker argues this is a travesty for PTSD patients who have very few options. He focuses on the reasoning the FDA gave for denying approval: the trial was functionally unblinded. Typically, trials use placebo and active drug arms with participants unaware of which treatment they receive, to ensure that observed effects are not merely placebo. The FDA claimed that patients knew whether they were on the MDMA-based therapy because some experienced euphoria, a side effect of the treatment. Therefore, the therapy could appear to work due to unblinding and a placebo effect, rather than a true therapeutic benefit. The speaker emphasizes that the possibility of euphoria being part of the drug’s mechanism—and thus related to its therapeutic effect—was ignored in their assessment, and that this unblinding was, in his view, anticipated by the FDA before agreeing to the phase three protocol, which also added tens or hundreds of millions of dollars in development costs.
The speaker criticizes the public record, including biotech press coverage, for focusing on “trial irregularities” or an unblinding issue rather than on the broader cost-benefit and mechanistic considerations. He asserts that the public is left with the notion that there were unblinding issues, not recognizing that the unblinding related to the drug’s therapeutic properties was anticipated and approved by the FDA. He concludes that the episode reveals how the bureaucratic machinery operates, with advisory committees and briefing documents shaping outcomes in a way that aligns with the FDA’s underlying aims.